Calamos Advisors’s Core Laboratories CLB Stock Holding History

Calamos Advisors’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,113	Closed	-$984K	–	1170
2022 Q1	$984K	Buy	+31,113	New	+$872K	﹤0.01%	1037
2015 Q2	–	Sell	-6,300	Closed	-$658K	–	690
2015 Q1	$658K	Hold	6,300	–	–	﹤0.01%	570
2014 Q4	$758K	Hold	6,300	–	–	0.01%	559
2014 Q3	$922K	Buy	+6,300	New	+$972K	0.01%	519

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Calamos Advisors's CLB Position: Q2 2022 in Review

Calamos Advisors sold out of Core Laboratories (CLB) in Q2 2022, closing a stake of 31,113 shares — an estimated $984K sold.

Calamos Advisors first reported a position in CLB in Q3 2014 and held it in 4 quarters. The position peaked at $984K in Q1 2022. 176 funds tracked by Wall St. Rank hold CLB as of Q2 2022.

Calamos Advisors reported no remaining Core Laboratories position as of Q2 2022 after selling out during the quarter.
Calamos Advisors sold 31,113 Core Laboratories shares in Q2 2022, an estimated $984K.
Calamos Advisors first reported a position in Core Laboratories in Q3 2014 and held it in 4 quarters.
Calamos Advisors's Core Laboratories position peaked at $984K in Q1 2022.
176 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.